These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27371974)

  • 1. Modeling complement-driven diseases in transgenic mice: Values and limitations.
    Ueda Y; Gullipalli D; Song WC
    Immunobiology; 2016 Oct; 221(10):1080-90. PubMed ID: 27371974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diseases of complement dysregulation-an overview.
    Wong EKS; Kavanagh D
    Semin Immunopathol; 2018 Jan; 40(1):49-64. PubMed ID: 29327071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and future pharmacologic complement inhibitors.
    Risitano AM
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):561-82. PubMed ID: 26043392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New Complement Therapeutics in Complement-Related Diseases].
    Wakamiya N; Ohtani K; Hidaka Y; Inoue N
    Brain Nerve; 2019 Jun; 71(6):555-564. PubMed ID: 31171752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic complement inhibition – from experimental to clinical medicine.
    Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE
    Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement in hemolytic anemia.
    Brodsky RA
    Blood; 2015 Nov; 126(22):2459-65. PubMed ID: 26582375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement biology for hematologists.
    Duval A; Frémeaux-Bacchi V
    Am J Hematol; 2023 May; 98 Suppl 4():S5-S19. PubMed ID: 36688486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system.
    Schmidt CQ; Smith RJH
    Immunol Rev; 2023 Jan; 313(1):376-401. PubMed ID: 36398537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
    Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
    Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
    Mastellos DC; Reis ES; Yancopoulou D; Risitano AM; Lambris JD
    Semin Hematol; 2018 Jul; 55(3):167-175. PubMed ID: 30032754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementopathies.
    Baines AC; Brodsky RA
    Blood Rev; 2017 Jul; 31(4):213-223. PubMed ID: 28215731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement Inhibitors in Clinical Trials for Glomerular Diseases.
    Zipfel PF; Wiech T; Rudnick R; Afonso S; Person F; Skerka C
    Front Immunol; 2019; 10():2166. PubMed ID: 31611870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition.
    Hanna RM; Barsoum M; Vandross A; Kurtz I; Burwick R
    Curr Opin Nephrol Hypertens; 2019 May; 28(3):278-287. PubMed ID: 30865166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement and the prothrombotic state.
    Schmidt CQ; Schrezenmeier H; Kavanagh D
    Blood; 2022 Mar; 139(13):1954-1972. PubMed ID: 34415298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.
    Vernon KA; Ruseva MM; Cook HT; Botto M; Malik TH; Pickering MC
    J Am Soc Nephrol; 2016 May; 27(5):1334-42. PubMed ID: 26374608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement in hemolytic anemia.
    Brodsky RA
    Hematology Am Soc Hematol Educ Program; 2015; 2015():385-91. PubMed ID: 26637747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Goodship TH; Cook HT; Fakhouri F; Fervenza FC; Frémeaux-Bacchi V; Kavanagh D; Nester CM; Noris M; Pickering MC; Rodríguez de Córdoba S; Roumenina LT; Sethi S; Smith RJ;
    Kidney Int; 2017 Mar; 91(3):539-551. PubMed ID: 27989322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.
    Varela JC; Brodsky RA
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1113-24. PubMed ID: 24168416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.